Dutch CDMO BioConnection to exhibit at the BIO International Convention in San Diego

 

 

 

GMP contract manufacturing for the aseptic fill & finish and freeze-drying of sterile drug products in vials or syringes

 

  BioConnection, an independent CDMO (Contract Development Manufacturing Organization) based in Oss, The Netherlands, specialized in GMP-certified manufacturing of sterile drug products in vials and syringes, will be exhibiting at the forthcoming BIO International Convention in San Diego, US, from 13 to 16 June. BioConnection will be exhibiting at booth #1345. Our specialists will be happy to tell you more about BioConnection’s GMP services for the aseptic fill & finish and freeze-drying of sterile drug products (in vials or syringes).

Over the past 17 years BioConnection has developed into an all-round CDMO, perfectly scaled for servicing small to middle sized (bio)pharmaceutical companies in the development and GMP manufacturing of sterile drug products in batch sizes that match the volumes that are required for personalized medications, clinical trial programs and commercial purposes. In 2021, BioConnection expanded its production capacity with a brand-new large-scale filling line, significantly increasing its annual production capacity up to 40 million vials for liquid products and up to 4 million vials for freeze-dried products. The new production line is validated according to EMA and US-FDA quality guidelines.

The industry

The pharmaceutical industry is evolving towards targeted drug delivery platforms, complex molecules such as biologics and niche indications, all of which require a wider range of development capabilities and manufacturing capacity to ensure accelerated speed to market. As a result, pharmaceutical companies, both large and small, look for strategic, integrated partners like BioConnection, that can seamlessly deliver on multiple levels, thereby reducing complexity in their supplier network. In order to establish this next level in services, capacity and quality, and to remain fully compliant with the constantly increasing regulatory demands, BioConnection therefore foresees significant growth of its operations in the coming period.